The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT). Issue 1 (December 2015) - Huntgeburth, Michael; Kießling, Johannes; Weimann, Gerrit; Kiepsel, Verena; Saleh, Soundos; Hunzelmann, Nicolas; Rosenkranz, Stephan